SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 58.17+3.9%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John Metcalf who wrote (7229)10/26/2002 6:53:58 PM
From: Biotech Jim  Read Replies (1) of 52153
 
John-

I believe it was PFE that identified PDE5 as the erectile dysfunction target in man, as a consequence of exploring PDE5 inhibitors for cardio indications. This represents major innovation, even if it was found by accident. This is what utility patents are for. I do not know whether they will ultimately prevail, but I feel that their approach is valid. It does not seem fair to compare SSRIs with this, since there was a strong history of monoaminergic mechanisms attendant to both depression and psychosis. Not so for erectile dysfunction. Look also at the utility that MLNM has for mc4 receptor agonism and obesity/weight control. Same concept there. I could go on.

I'm nor saying that others may not develop a better mouse trap, just that they discovered the concept of the mouse trap and in some view they should help real some of each's rewards here.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News